ĐÁNH GIÁ ĐÁP ỨNG VÀ TÁC DỤNG KHÔNG MONG MUỐN CỦA PHÁC ĐỒ TC TRONG ĐIỀU TRỊ BỔ TRỢ TRƯỚC UNG THƯ LƯỠI TẠI BỆNH VIỆN K

Abstract

Objectives: To evaluate the response rate and the toxicity of the neoadjuvant chemotherapy with taxane plus cisplatin in patients with mobile tongue cancer. Patients and methods: 125 patients with stage III, IV (M0) mobile tongue cancer who were treated neoadjuvant chemotherapy with taxane plus cisplatin at K hospital from 1/2012 to 10/2018. Results: The complete response rate is 14,4%, partial response rate is 44%, stable disease is 36,5 and progressive disease is 4,8% after 3 cycles. The response rates for age groups ≤ 50 and > 50 are 61.8% and 55.7%, respectively, and male versus female is 55.1% and 70.4%. The response rates of patients without or with lymph node metastases were 72.9% and 45.5%, respectively, the difference was statistically significant. Patients with stage III have a higher response rate than patients with stage IV, respectively 64.9% and 55.7%. Most patients have grades 1, 2 anemia. The grade 3, 4 leucopenia are 24.3% and 9.3%, respectively. There was no case of grade 3,4 thrombocytopenia. Other side effects: vomiting, nausea, myalgia, peripheral neurological complications, mainly were grade 1,2. Conclusion: Neoadjuvant chemotherapy with taxane plus cisplatin shows good response and low toxicity, it improves the results of treating patients with stage III, IV(M0) mobile tongue cancer.